Director
AstraZeneca, Sweden
Joanna Rejman obtained her PhD title in 2000. Subsequently (2000-2007), she did two PostDocs at University of Groningen (NL) and San Raffaele Hospital in Milan (Italy) studying cell-biological aspects of cell transfection with non-viral systems and therapeutic strategies towards cystic fibrosis. She held researcher positions at esteemed European Universities (2008-2015) – Gent University, Philipps University Marburg and Ludwig-Maximilian University Munich again focusing on non-viral delivery systems, both polymers and lipids, to treat rare diseases and develop vaccines. Prior to joining AZ she worked at CureVac, Tübingen (Germany). She held positions of increasing responsibility in the department of product design and formulation and therapeutic area eye and lung as an associate director and team leader. She was a PI on prestigious collaborations with Harvard and Yale. Turning an mRNA molecule into an effective drug has been a subject of her research for more than 15 years. She has published more than 50 research papers and is a coinventor of several patents. She has an excellent track record for the supervision and development of scientists at the early career stages (Master students, PhD students, PostDocs).
Disclosure information not submitted.
Workshop: Therapeutic Genome Editing Tools, Delivery Systems, Prospects and Challenges
Monday, July 8, 2024
1:00 PM – 5:00 PM CET
